Acarix AB (publ) has completed a new share issue with preferential rights for Acarix’ existing shareholders. Through the transaction, Acarix will receive approximately SEK 56 million before costs related to the rights issue.
Acarix is a Swedish MedTech company, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
The proceeds from the private placement will be used primarily for the commercialization process of the CADScor®System in accordance with the company’s established market strategy.
Baker McKenzie acted as legal advisor to Acarix in connection with the transaction. Baker McKenzie’s team consisted of Joakim Falkner, Stefan Balazs, Ian Gulam and Marlene Wiklund.